Creative Biolabs Introduces One-Stop CAR-T Preclinical In Vivo Assay Services

SHIRLEY, NY, UNITED STATES - Sep 7, 2020 - Chimeric antigen receptor (CAR) T cell therapy represents the culmination of research in both immunology and oncology fields. According to the latest research, this novel therapy has been proved to be successful in the treatment of hematologic malignancies with response rates as high as 70-90% in some cases, which shows great potential in tumor treatment.

As a world-leading service provider in the field of TCR and CAR T&NK cell immune therapy development, Creative Biolabs has released a portfolio of CAR-T preclinical in vivo assay services covering construction of Xenograft animal model, strategies to harness cytokine release syndrome, efficacy test of CAR-T, viability and bio-distribution study of CAR-T, toxicity evaluation of CAR-T, and quality control for in vivo assays.

· Efficacy Test of CAR-T

With years of preclinical in vivo research and project management experience, Creative Biolabs is confident to utilize appropriate animal models, design comprehensive research practices and handle high-quality in vivo studies to provide therapeutic efficacy test service. Scientists at Creative Biolabs are skillful in related technologies, including in vivo imaging, flow cytometry, histologic and pathologic analysis, and clinical observation.

· Toxicity Evaluation of CAR-T

Although having demonstrated great efficacy in hematologic malignancies and some solid tumors in early phase clinical trials, CAR-T cells are still found to have the possibility to elicit some expected or unexpected toxicities. Evaluating of the toxicity on animal models is of great importance in the research and development of efficient CAR-T therapy, and thus Creative Biolabs spares no effort in providing CAR-T cell toxicity evaluation service, such as clinical observation, cytokine release analysis, tumor lysis analysis, on-target/off-tumor toxicologic effect analysis, tumorigenicity study, etc.

· Viability and Bio-distribution Study of CAR-T

Creative Biolabs also provides preclinical viability and bio-distribution analysis services for CAR-T cell therapy. The experienced technician team is able to conduct various related tests on the most appropriate models with the most advanced techniques (such as bioluminescence imaging, flow cytometry analysis, quantitative PCR, histologic analysis). The viability and bio-distribution study focuses on in vivo proliferation, survival and long-term persistence of CAR-T cells, T cell migration and distribution, memory T cell response, T cell Perseverance, and efficacy of next generation CAR.

All these CAR-T preclinical in vivo assays at Creative Biolabs can be conducted targeting the following targets:

For hematologic malignancies: BCMA, CD123, CD138, CD20, CD22, Igk, CS1, NKG2D-Ligand, etc.

For solid tumors: EGFR, HER2, FAP, NY-ESO-1, MUC16, ROR1, CEA, PSMA, MET, etc.

With all studies performed in GLP-compliant and IACUC-regulated facility, Creative Biolabs aims at providing the best-characterized therapeutic efficacy test services for CAR-T cell therapy development to help global customers and expedite their IND application.

More information can be reached on https://www.creative-biolabs.com/car-t/.

About Creative Biolabs

With more than 15 years’ history, Creative Biolabs has talented and well-trained scientists located in different continents working closely with partners from the entire world to develop and produce medicines of tomorrow. Specifically, Creative Biolabs provides the one-stop custom CAR-T therapy development services that cover the entire new drug development pipeline.